Second Genome, a venture-backed Bay Area based life sciences company, is committed to improving the quality of human health through microbiome-based personalized medicine. Founded in 2009 by leading experts in microbial research, molecular diagnostics, and biotechnology R&D, Second Genome is using its proprietary Microbiome Signature Discovery platform to generate novel insights relating the microbiome with a wide range of human health disorders. Working with academic and commercial collaborators, Second Genome is developing novel diagnostic tools and therapies for unmet needs in gastrointestinal disorders.
The company has established a pipeline of microbiome modulators that impact infection, inflammation, and metabolic diseases. Second Genome entered into the first ever big pharmaceutical partnership focused on microbiome drug discovery with Janssen Biotech, Inc. in June 2013 for new treatments for ulcerative colitis.
Current Team (5)Update
Funding Rounds (3) - $11.5MUpdate
Board Members and Advisors (6)Update
1700 Owens Street, 5th Floor
San Francisco, CA 94158